Your browser doesn't support javascript.
loading
Epilepsy lifetime prevalence in Iran: a large population- based national survey.
Pakdaman, Hossein; Harandi, Ali Amini; Gharagozli, Koroush; Alaeddini, Farshid; Esfandani, Akram; Mirbehbahani, Seyed Hamidreza; Doroudi, Taher; Kolivand, Pirhossein; Bahrami, Parviz; Kazemi, Hadi.
Afiliación
  • Pakdaman H; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Harandi AA; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ali.amini.harandi@gmail.com.
  • Gharagozli K; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Alaeddini F; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Esfandani A; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mirbehbahani SH; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Doroudi T; Shefa Neuroscience Research Center, Khatam-Ol-Anbia Hospital, Tehran, Iran.
  • Kolivand P; Shefa Neuroscience Research Center, Khatam-Ol-Anbia Hospital, Tehran, Iran.
  • Bahrami P; Shefa Neuroscience Research Center, Khatam-Ol-Anbia Hospital, Tehran, Iran.
  • Kazemi H; Shefa Neuroscience Research Center, Khatam-Ol-Anbia Hospital, Tehran, Iran.
Sci Rep ; 11(1): 9437, 2021 05 03.
Article en En | MEDLINE | ID: mdl-33941831
ABSTRACT
Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95% CI 15.4-17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3%), generalized epilepsy (38%) and unknown types of epilepsy (2.7%) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15-19 years old [32.7 per 1000 persons (95% CI 29.1-36.8)] and it was higher in male (53.8%) than female (46.2%) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tamizaje Masivo / Epilepsia Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Aspecto: Patient_preference Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Asia Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tamizaje Masivo / Epilepsia Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Aspecto: Patient_preference Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Asia Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Irán